(Total Views: 740)
Posted On: 03/24/2021 2:51:27 PM
Post# of 154896
Excerpt from the article.
3. Case DESCRIPTION
The male subject was admitted to a London teaching hospital in the United Kingdom with confirmed nasopharyngeal swabs positive for SARS-CoV-2 infection by reverse transcriptase polymerase chain reaction (RT–PCR). He is of mixed race in his late 50’s with critical COVID-19. Other pertinent characteristics include a BMI of 37 kg/m2, prior smoker, and well-controlled hypertension. Following a positive test for SARS-CoV-2 infection, the subject was admitted to hospital with dyspnoea and pyrexia (Day 0). The subject received several investigational treatments prior to treatment with leronlimab. Upon admission, the subject was treated with dexamethasone for 10 days. Remdesivir was initiated on Day 1; a plasma exchange was administered on Day 4 for 10 days. Other drug interventions included intravenous antibiotics. The subject’s condition continued to deteriorate, and ECMO was initiated on Day 19. Four doses of leronlimab (700 mg), obtained from CytoDyn (CytoDyn inc. WA, USA) through an Emergency Investigational New Drug (EIND) application, were administered on Days 79, 86 and 93 and 100 post diagnosis. The subject responded extremely rapidly and was weaned off ECMO between Days 82 to 84, and he was discharged from the ECMO intensive care unit on Day 91. No adverse safety issues were identified with the administration of leronlimab in this subject. Oxygen therapy and intravenous antibiotics for ventilator-associated pneumonia were administered post weaning off ECMO. At last follow up the subject’s condition continues to improve and he is undergoing rehabilitation.
Love it! London news is good news.
3. Case DESCRIPTION
The male subject was admitted to a London teaching hospital in the United Kingdom with confirmed nasopharyngeal swabs positive for SARS-CoV-2 infection by reverse transcriptase polymerase chain reaction (RT–PCR). He is of mixed race in his late 50’s with critical COVID-19. Other pertinent characteristics include a BMI of 37 kg/m2, prior smoker, and well-controlled hypertension. Following a positive test for SARS-CoV-2 infection, the subject was admitted to hospital with dyspnoea and pyrexia (Day 0). The subject received several investigational treatments prior to treatment with leronlimab. Upon admission, the subject was treated with dexamethasone for 10 days. Remdesivir was initiated on Day 1; a plasma exchange was administered on Day 4 for 10 days. Other drug interventions included intravenous antibiotics. The subject’s condition continued to deteriorate, and ECMO was initiated on Day 19. Four doses of leronlimab (700 mg), obtained from CytoDyn (CytoDyn inc. WA, USA) through an Emergency Investigational New Drug (EIND) application, were administered on Days 79, 86 and 93 and 100 post diagnosis. The subject responded extremely rapidly and was weaned off ECMO between Days 82 to 84, and he was discharged from the ECMO intensive care unit on Day 91. No adverse safety issues were identified with the administration of leronlimab in this subject. Oxygen therapy and intravenous antibiotics for ventilator-associated pneumonia were administered post weaning off ECMO. At last follow up the subject’s condition continues to improve and he is undergoing rehabilitation.
Love it! London news is good news.
(13)
(0)
